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Dysthymia is a depressive mood disorder characterized by chronic and persistent but mild depression. It is often diﬃcult to be
distinguished from major depression, speciﬁcally in its partially remitted state because “loss of interest” or “apathy” tends to
prevail both in dysthymia, and remitted depression. Apathy may also occur in various psychiatric and neurological disorders,
including schizophrenia, stroke, Parkinson’s disease, progressive supranuclear palsy, Huntington’s disease, and dementias such as
Alzheimer’s disease, vascular dementia, and frontotemporal dementia. It is symptomatologically important that apathy is related
to, but diﬀerent from, major depression from the viewpoint of its causes and treatment. Antidepressants, especially noradrenergic
agents, are useful for depression-related apathy. However, selective serotonin reuptake inhibitors (SSRIs) may be less eﬀective for
apathy in depressed elderly patients and have even been reported to worsen apathy. Dopaminergic agonists seem to be eﬀective for
apathy. Acetylcholine esterase inhibitors, methylphenidate, atypical antipsychotics, nicergoline, and cilostazol are another choice.
Medication choice should be determined according to the background and underlying etiology of the targeting disease.
1.Dysthymia
Dysthymia is a depressive mood disorder that is character-
ized by chronic, persistent but mild depression, aﬀecting 3–
6% of individuals in the community [1, 2] and as many as
36% of outpatients in mental health settings [3]. Although
by deﬁnition, the depressed mood of dysthymia is not severe
enoughtomeetthecriteriaformajordepressivedisorder,itis
accompaniedbysigniﬁcantsubjectivedistressorimpairment
of social, occupational, or other important activities as a
result of mood disturbance [4]. Dysthymia manifests as a
depressed mood persisting for at least two years (one year for
children or adolescents) that lasts for most of the day, occurs
on more days than not, and is accompanied by at least two of
the following symptoms:
(1) poor appetite or overeating,
(2) insomnia or hypersomnia,
(3) low energy or fatigue,
(4) low self-esteem,
(5) poor concentration or diﬃculty making decisions,
(6) feelings of hopelessness.
To diagnose dysthymia, major depressive episodes must
not have occurred during the ﬁrst two years of the illness
(one year in children or adolescents), and there should be no
history of mania. The Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-
TR) [5] states that transient euthymic episodes lasting for up
to two months may occur during the course of dysthymia. In
the past, dysthymia has had several other names, including
depressive neurosis, neurotic depression, depressive person-
ality disorder, and persistent anxiety depression.
DSM-IV-TR categorizes dysthymia according to several
coursespeciﬁers:(1)earlyonsetifsymptomsbeginbeforethe
age of 21 years, (2) late onset if symptoms begin at age 21 or
later, and (3) dysthymia with atypical features if symptoms2 Depression Research and Treatment
include increased appetite or weight gain, hypersomnia,
a feeling of leaden paralysis, and extreme sensitivity to
rejection.
It is often diﬃcult to diﬀerentiate dysthymia from major
depression speciﬁcally in patients with partial remission or
partialresponsetotreatment.Majordepressivedisorder,dys-
thymia, double depression, and some apparently transient
dysphorias may all be manifestations of the same disease
process. These varieties of depressed mood states, while
distinct diagnostic entities, share similar symptoms and
respond to similar pharmacologic and psychotherapeutic
approaches. Due to the stigma still associated with depres-
sion, many people with this disorder may be unrecognized
anduntreated.Althoughdysthymiahaslongbeenconsidered
to be less severe than major depression, the consequences
of this condition are increasingly recognized as potentially
grave, including severe functional impairment, increased
morbidity from physical disease, and even an increased risk
of suicide.
The pathophysiology of dysthymia is not fully under-
stood. Approximately 30% of individuals with dysthymia
show a switch to hypomanic episodes at some stage [6].
Most people, especially those with early onset dysthymia,
have a family history of mood disorders, including bipolar
disorder. One or both parents may have suﬀered from
major depression. A family history of this illness makes it
more likely for dysthymia to appear in the teenage years
or early 20s. Compared with major depression, patients
with dysthymia tend to have more subjective symptoms and
less dramatic psychomotor disturbance or neurovegetative
symptoms including abnormalities of sleep, appetite, and
energy levels. A longitudinal prospective study revealed that
76% of dysthymic children develop major depression, and
13% develop bipolar disorder over follow-up periods of 3–
12 years [7]. In the other study, it should be noted that
around75%ofpeoplewithdysthymiameetthecriteriaforat
least one major depressive episode, and this combination is
referred to as double depression [8]. Persons with dysthymia
who have major depressive episodes tend to suﬀer from
depression for long periods and spend less time fully
recovered [9]. In a 10-year follow-up study of persons with
dysthymia, 73.9% showed recovery from dysthymic disorder,
with a median time to recovery of 52 months, but the
estimated risk of relapse into another period of chronic
depression including dysthymia was 71.4%, most commonly
within three years [10].
The validity of making a distinction between depressive
personality disorder and dysthymia has been a matter of
debate since depressive personality disorder and dysthymia
are both classiﬁed among the lesser severity spectrum
of depressive disorders. Depressive personality disorder is
characterized by a gloomy or negative outlook on life,
introversion, a tendency toward self-criticism, and pes-
simistic cognitive processes, with fewer than mood and
neurovegetative symptoms, seen in dysthymia. Dysthymia or
depression may coexist with depressive personality disorder,
and persons who have depressive personality disorder are at
greater risk of developing dysthymia than healthy persons
after followup for 3 years [11].
2. Treatment for Dysthymia
The best treatment for dysthymia appears to be a com-
bination of psychotherapy and medication. The positive
clinicalresponsetomedicationslikeselectiveserotoninreup-
take inhibitors (SSRIs) [12–19], serotonin norepinephrine
reuptake inhibitors (SNRIs) [20, 21], and tricyclic antide-
pressants (TCAs) [14, 15] suggests that serotoninergic and
noradrenergic systems involve the mechanism of dysthymia.
As y s t e m a t i cr e v i e w[ 22, 23] of antidepressant treatment
for dysthymia suggests that SSRIs, TCAs, and monoamine
oxidase inhibitors are all equally eﬀective, but SSRIs may
be slightly better tolerated. Success has also been reported
with more noradrenergic agents, such as mirtazapine, nefa-
zodone, venlafaxine, duloxetine, and bupropion. Second-
generation antipsychotics showed beneﬁcial eﬀects com-
pared to placebo for major depressive disorder or dys-
thymia, but most second-generation antipsychotics have
shown worse tolerability, mainly due to sedation, weight
gain, or laboratory data abnormalities such as prolactin
increase. Some evidence indicated beneﬁcial eﬀects of low-
dose amisulpride for dysthymic people [24].
Psychotherapy and medication are both eﬀective treat-
ment modalities for dysthymia and their use in combination
is common. There are many diﬀerent types of psychother-
apy, including cognitive behavioral therapy, psychodynamic,
and insight-oriented or interpersonal psychotherapy, which
are available to help persons with dysthymia. Cognitive
Behavioral Analysis System of Psychotherapy (CBASP) [25]
has been attracting more attention for the treatment of
chronic depression. CBASP is a form of psychotherapy
that was speciﬁcally developed for patients with chronic
depression. Its core procedure is called “situational analysis”
and is a highly structured technique that teaches chronically
depressed patients how to handle problematic interpersonal
encounters. It encourages patients to focus on the conse-
quencesoftheirbehaviorandtouseasocialproblem-solving
algorithm to address interpersonal diﬃculties. CBASP is
more structured and directive than interpersonal psy-
chotherapy and diﬀers from cognitive therapy by focusing
primarily on interpersonal interactions, including interac-
tions with therapists. Through this psychotherapy, patients
come to recognize how their cognitive and behavioral
patternsproduceandperpetuateinterpersonalproblemsand
learn how to remedy maladaptive patterns of interpersonal
behavior.Thecombinationofmedicationandpsychotherapy
m a yb em u c hm o r ee ﬀective than either one alone [26].
3.Apathy
Dysthymiaisessentiallydeﬁnedbytheexistenceofdepressive
symptoms at some level. However, some patients who are
treated for dysthymia only present with loss of interest and
do not have a depressed mood. This condition should be
regarded as apathy. The term “apathy” is derived from the
Greek “pathos” meaning passion, that is, apathy means “lack
of passion”. Marin [27] deﬁned the apathy syndrome as a
syndrome of primary lack of motivation, that is, loss of
motivation that is not attributable to emotional distress,Depression Research and Treatment 3
Table 1: Diagnostic criteria for apathy.
Lack of motivation relative to the patient’s previous level of functioning or the standards of his or her age and culture, as indicated either
by subjective account or observation by others.Presence, with lack of motivation, of at least one symptom belonging to each of the fol-
lowing three domains.
(i) Diminished goal-directed behavior:
(a) lack of eﬀort,
(b) dependency on others to structure activity.
(ii) Diminished goal-directed cognition:
(a) lack of interest in learning new things or in new experiences,
(b) lack of concern about one’s personal problems.
(iii) Diminished emotion:
(a) unchanging aﬀect,
(b) lack of emotional responsivity to positive or negative events.
The symptoms cause clinically signiﬁcant distress or impairment in social, occupational, or other important areas of functioning. The
symptoms are not due to a diminished level of consciousness or the direct physiological eﬀects of a substance (e.g., a drug of abuse, a
medication).
Adapted from Starkstein [30].
Table 2: Possible medications for apathy.
Category Class Main background disease Representative drug name
Antidepressants
SSRIs∗
SNRIs∗∗
NaSSAs∗∗∗
DNRIs∗∗∗∗
Tetracyclic antidepressants
Tricyclic antidepressants
Depression
Fluvoxamine, Paroxetine
Sertraline
Milnacipran
Mirtazapine
Bupropion
Maprotiline
Amoxapine
Nortriptyline
Dopamine stimulants Dopamine agonists Parkinson’s disease,
depression (?)
Bromocriptine
Pramipexrole
Ropinirole
Amantadine
MAO-B inhibitor Selegiline
Antipsychotic agents Atypical antipsychotic
agents
Negative symptoms
(apathy-like symptoms) of
schizophrenia
Clozapine, Risperidone,
Olanzapine, Quetiapine,
Ziprasidone
Psychostimulants Dopaminergic agents Primary apathy or apathy
syndrome
Methylphenidate
Pemoline
Amphetamine
Modaﬁnil
Antidementia agents Cholinesterase inhibitors Alzheimer’s disease
Donepezil
Galantamine
Rivastigmine
Metrifonate
Tacrine
Pyrrolidone-type nootropic
agent Stroke, Alzheimer’s disease Neﬁracetam
Cerebral circulation
and metabolism
stimulants
Ergot alkaloid Stroke Nicergoline
Antiplatelet drugs Phosphodiesterase
inhibitor Cilostazol
∗Selective serotonin reuptake inhibitors: there have been a few reports that SSRIs are not eﬀective for apathy. ∗∗Serotonin-noradrenaline reuptake inhibitors.
∗∗∗Noradrenergic and speciﬁc serotonergic antidepressants. ∗∗∗∗Noradrenaline-dopamine reuptake inhibitors.4 Depression Research and Treatment
intellectualimpairment,ordiminishedconsciousness.Stark-
stein [28] described the features of apathy as lack of moti-
vation characterized by diminished goal-oriented behavior
and cognition, and a diminished emotional connection to
goal-directed behavior. Levy and Dubois [29] proposed that
apathy could be deﬁned as the quantitative reduction of self-
generated voluntary and purposeful behavior. At present,
apathy is treated symptomatically. There is no decision tree
for apathy in DSM-IV-TR, but there is a possibility that
apathy will come to be managed independently from mood
disorders if the mechanisms involved or treatment strategy
is more fully established in the future. Marin [27]a n d
Starkstein [30] have suggested diagnostic criteria for this
condition. As the basis of speciﬁc diagnostic criteria for apa-
thy, abnormalities in aspects of emotion, cognition, motor
function, and motivation have been suggested. Marin has
also developed an apathy rating scale [31], while diagnostic
criteria for apathy have been proposed by Starkstein et al.
(Table 1).
Apathy has received increasing attention because of its
eﬀects on emotion, behavior, and cognitive function. It
seems likely that apathy in persons with depression results
from alterations of the emotional and aﬀective processing,
butitmaytypicallyoccurintheabsenceofadepressedmood
(Figure 1).
Apathy occurs in persons with a variety of psychi-
atric and neurological disorders including schizophrenia
[32, 33], stroke [34, 35], traumatic brain injury [36],
Parkinson’s disease [28, 37, 38], progressive supranuclear
palsy [38], Huntington’s disease [39, 40], and dementias
such as Alzheimer’s disease [30, 41, 42], vascular dementia
[43], frontotemporal dementia [41, 42], and dementia due
to HIV [44]. Marin et al. [45]e v a l u a t e dﬁ v es u b g r o u p s
(healthy elderly adults, patients with left hemispheric stroke,
right hemispheric stroke, Alzheimer’s disease, and major
depression) by using the apathy evaluation scale [31]a n d
the Hamilton rating scale for depression [46]. Mean apathy
scores were signiﬁcantly higher than healthy elderly scores
in right hemispheric stroke, Alzheimer’s disease, and major
depression. Elevated apathy scores were associated with
low depression in Alzheimer’s disease, high depression in
major depression, and intermediate scores for depression in
right hemispheric stroke. The prevalence of elevated apathy
scores ranged from 73% in Alzheimer’s disease, 53% in
major depression, 32% in right hemispheric stroke, 22% in
left hemispheric stroke, and 7% in normal subjects. They
found that the level of apathy and depression varied among
diagnostic groups although apathy and depression were
signiﬁcantly correlated within each group. Thus, apathy is
most often seen clinically within the setting of depression,
dementia, or stroke, and problems related to apathy tend to
be important because of its frequency, increasing prevalence,
impact on daily life, poorer rehabilitation outcomes after
stroke, and burden on caregivers.
Levy et al. [42, 47] found that patients with frontotem-
poral dementia and progressive supranuclear palsy could
be discriminated from patients with Alzheimer’s disease by
their more severe apathy and relatively less severe depression.
Furthermore, they reported that apathy was not correlated
with depression in a combined patient sample, including
those with Alzheimer’s disease, frontotemporal dementia,
progressive supranuclear palsy, Parkinson’s disease, and
Huntington’s disease. Apathy, but not depression, was cor-
related with lower cognitive function as measured by the
mini mental state examination [48]. These results imply
that apathy might be a speciﬁc neuropsychiatric syndrome
that is distinct from depression but is associated with both
depression and dementia. Symptomatologically, it is impor-
tant to understand that apathy can occur concomitantly
with depression, but is usually diﬀerent from it. Depression
is a “disorder of emotion”, while apathy is a “disorder of
motivation”. Starkstein et al. [34] studied the frequency
of apathy among stroke patients with major depression,
minor depression, or no depression. A fairly large number
(23%) of their patients had signiﬁcant apathy. The apathetic
patients were older, had a higher frequency of major (but not
minor) depression, had more severe physical and cognitive
impairment, and had lesions involving the posterior limb of
the internal capsule. In their study, there was a signiﬁcantly
higher frequency of apathy among the patients with major
depression but not those with minor depression or no
depression. These ﬁndings indicate that although major
depression and apathy occur independently, apathy remains
signiﬁcantly associated with major depression (but not with
minor depression). This is consistent with the results of
previous studies that have diﬀerentiated between major and
minordepression,includingdiﬀerencesofcognitivefunction
and cortisol suppression after dexamethasone administra-
tion [49, 50], which were seen in patients with major
depression but not minor depression.
Apathy is often seen in patients with lesions of the pre-
frontal cortex [51, 52] and is also frequent after focal
lesions of speciﬁc structures in the basal ganglia such as
the caudate nucleus, the internal pallidum, and the medial
dorsal thalamic nuclei [53–56]. Apathy is, therefore, one
of the clinical sequelae of disruption of the prefrontal
cortex-basal ganglia axis, which is one of the functional
systems involved in the origin and control of self-generated
purposeful behavior. Anatomical localization of regional
dysfunction associated with apathy and depression appears
to overlap considerably. Depression has been reported to be
more frequent when focal lesions are anterior and left-sided
[57]. Levy and Dubois [29] proposed that the mechanisms
responsibleforapathycouldbedividedintothreesubtypesof
disrupted processing: “emotional-aﬀective”, “cognitive”, and
“autoactivation” loss of psychic self-activation.
4. Treatment for Apathy (Table 2)
Taking into consideration the facts that apathy is related to
cognitive function and disruption of the prefrontal cortex-
basal ganglia axis, apathy can be considered to resemble
subcortical dementia and to be treatable using dopaminergic
agents in central nervous system. A growing number of
reports have documented the treatment of apathy with
a variety of psychoactive agents. Various small studies
have indicated that psychostimulants, dopaminergics, andDepression Research and Treatment 5
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Suicidal ideation
Vegetative symptoms
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Figure 1: Apathy versus depression.
cholinesterase inhibitors might be of beneﬁt for this syn-
drome. However, there is no current consensus about
treatment for apathy, and information on pharmacotherapy
for this condition mainly depends upon underlying etiology
and background disease. For example, dopamine agonists
appear to be promising for ameliorating apathy in patients
with Parkinson’s disease while atypical antipsychotics used
in schizophrenia and cholinesterase inhibitors have been
reported to be useful for treating apathy in Alzheimer’s
disease and other dementias. Therefore, the treatment of
apathyshouldbeselectedaccordingtoitsetiology.Depressed
patients with apathy should be given antidepressants, which
may also alleviate other symptoms. However, caution has
been raised about using SSRIs for depressed elderly persons
because it may worsen apathy [58]. Since frontal lobe
dysfunction is considered to be one of the causes of apathy,
patients with primary apathy may respond to psychostimu-
lants such as methylphenidate or dextroamphetamine. There
have also been reports about improvement of apathy and
cognitive function after stroke by treatment with cilostazol
[59]. As nonpharmacological methods, cranial electrother-
apy stimulation for apathy after traumatic brain injury
[60], and cognitive stimulation therapy for neuropsychiatric
symptoms in Alzheimer’s disease [61] might have some
value, but evidence awaits future studies.
Apathy syndrome is associated with many diseases, but
whether medications are applicable across this spectrum
of background diseases remains unknown. For example,
would cholinesterase inhibitors that are used in patients with
Alzheimer’s disease be eﬀective for apathy associated with
major depression? These issues should be examined in future
studies.
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